A Phase 1B Study of the Anti-PD-1 Monoclonal Antibody, Tislelizumab, in Combination with the Parp Inhibitor, Pamiparib, in Advanced Solid Tumors

Michael Friedlander, T. Meniawy, B. Markman, L. R. Mileshkin, Paul Harnett, M. Millward, J. Lundy, A. E. Freimund, C. Norris, J. Wu, V. Paton, L. Wang, B. Gao

Research output: Contribution to journalAbstract/Meeting Abstract

Original languageEnglish
Pages (from-to)58-59
Number of pages2
JournalAsia-Pacific Journal of Clinical Oncology
Volume14
Publication statusPublished - Aug 2018
Externally publishedYes

Cite this

Friedlander, M., Meniawy, T., Markman, B., Mileshkin, L. R., Harnett, P., Millward, M., Lundy, J., Freimund, A. E., Norris, C., Wu, J., Paton, V., Wang, L., & Gao, B. (2018). A Phase 1B Study of the Anti-PD-1 Monoclonal Antibody, Tislelizumab, in Combination with the Parp Inhibitor, Pamiparib, in Advanced Solid Tumors. Asia-Pacific Journal of Clinical Oncology, 14, 58-59.